Kohei Shitara, Medical oncologist at National Cancer Center Hospital East, shared on X:
“Excited to see the positive results from Phase 3 CLARITY-Gastric 01.
AZD0901, an anti-CLDN18.2 ADC, improved OS vs 2nd or later-line chemo in patients with CLDN18.2+ gastric/GEJ cancer.
Please stay tuned for more details.”
To which Tsung-Che Wu, Medical Oncologist at NTUH, added:
“Great news!
One subgroup I’ll be watching closely is patients with CLDN18.2 expression high enough for CLARITY-Gastric01 but below the zolbetuximab threshold. I’m also curious whether the KM curves and subsequent therapies can explain the OS benefit despite a negative PFS result.”
You can also read ‘CLARITY-Gastric01: Sonesitatug Vedotin Improves Overall Survival in 2L+ CLDN18.2-Positive Advanced Gastric/GEJ Cancers‘
